Milstein Lecture 2021: Organoids to model human diseases

Add to your list(s) Download to your calendar using vCal

• Hans Clevers, Professor in Molecular Genetics, Hubrecht Institute, Utrecht, The Netherlands
• Tuesday 30 November 2021, 11:00-12:00
• Zoom: https://mrc-lmb-cam-ac-uk.zoom.us/j/96610458150?pwd=RmI5RUZZU0JRNzBBNlh3NnFWQWpjZz09.

If you have a question about this talk, please contact Scientific Meetings Co-ordinator.

Stem cells are the foundation of all mammalian life. Stem cells build and maintain our bodies throughout life. Two types of stem cells are discerned. 1) Embryonic stem cells (ES cells) are briefly present in the early human or mouse embryo, a few days after fertilization. These ES cells can be grown indefinitely in the lab and have the potential to build each and every tissue in our body. Because of this ‘pluripotency’, ES cells hold great promise for therapeutic application in the field of regenerative medicine. It is also possible to take skin cells (or other cells) from adults and convert these in the lab into cells with ES properties, so called iPS cells. Many of the hurdles that ES cell technology have faced, do not exist for iPS cells. 2) Adult stem cells. Every organ in our body is believed to harbor its own dedicated stem cells. These adult stem cells replace tissue that is lost due to wear and tear, trauma and disease. Adult stem cells are highly specialized and can only produce the tissue in which they reside; they are ‘multipotent’. Examples are bone marrow stem cells that make all blood cells, skin stem cells and gut stem cells. Even the brain is now known to harbor its specialized stem cells. The adult stem cells allow us to live 80-90 years, but this comes at a cost: they are the cells that most easily transform into cancer cells. Both types of stem cells can be used to establish ‘organoids’, 3D structures established in a dish, that recapitulate many aspects of the organ they represent. Pluripotent stem cells can be taken through the developmental steps that establish organs during embryogenesis. This has worked particularly well for parts of the the central nervous system, the kidney and GI organs. We have shown that adult epithelial stem cells carrying the generic Lgr5 marker can be cultured under tissue-repair conditions and generate epithelial organoids directly from healthy and diseased organs such as the gut, the liver, the lung and the pancreas. Organoid technology opens a range of avenues for the study of development, physiology and disease, for drug development and for personalized medicine. In the long run, cultured mini-organs may replace transplant organs from donors and hold promise in gene therapy.

This talk is part of the MRC LMB Seminar Series series.

This talk is included in these lists:

• All Talks (aka the CURE list)
• Biology
• CCC talks for website
• Cambridge Immunology
• Centre for Health Leadership and Enterprise
• Liam
• Life Sciences
• Life Sciences
• ME Seminar
• MRC LMB Seminar Series
• Neurons, Fake News, DNA and your iPhone: The Mathematics of Information
• Zoom: https://mrc-lmb-cam-ac-uk.zoom.us/j/96610458150?pwd=RmI5RUZZU0JRNzBBNlh3NnFWQWpjZz09
• cri
• my_list
• other talks
• rc781

Note that ex-directory lists are not shown.